Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Allogeneic CAR T data keep CRISPR Therapeutics competitive

Readout does not shed light on concerns of unintended edits

October 12, 2021 11:47 PM UTC

With efficacy holding steady and no new serious safety issues, the latest data for CTX110 puts the allogeneic CAR T cell therapy from CRISPR Therapeutics in a position to compete with autologous products, but it’s not enough to provide relief for investors on edge since a competing program sparked safety concerns last week.

CRISPR Therapeutics AG (NASDAQ:CRSP) was off 8% to $94 in after-hours trading on Tuesday after announcing that the CD19-targeting allogeneic CAR T cell therapy led to an overall response rate of 58% in the intent-to-treat population of 24 large B cell lymphoma patients, a complete response of 38% and a favorable safety profile...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article